RxDoctor Payments Data

Anthony Isedeh, MD

Hospitalist · New Haven, CTNPI 1639445539

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $348 and has fallen 79.5% since, to $71 in 2025. Among hospitalist clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,287in general payments, 2019–2025

Across 82 payments — averaging $15.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$300
  • AbbVie$245
  • Pfizer$199
  • E.r. Squibb & Sons, L.L.C.$165
  • Novo Nordisk$144
  • AstraZeneca$91
  • plus $144 from 5 others

What the payments were for

  • Food & beverage$1,287100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,287 in reported general payments places this provider in the 90th percentile of 349 hospitalist providers in Connecticut.

See all hospitalist providers in Connecticut

Medicare billing

Part B allowed, 2024
$114,184
Medicare patients
985
Services billed
1,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban46$13,592
Amiodarone Hcl23$1,038
Mirtazapine19$741
Amlodipine Besylate47$468
Finasteride17$415
Atorvastatin Calcium48$411
Metformin Hcl26$356
Oxybutynin Chloride ErOxybutynin Chloride12$344
Carvedilol30$341
Lisinopril52$326
Potassium Chloride12$310
Donepezil Hcl12$309
Gabapentin54$282
Tamsulosin Hcl13$271
Metoprolol Succinate20$249

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$199$13,59246 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 349 hospitalist providers in Connecticut.

Other hospitalist in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →